Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

802 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study.
Brown JWL, Cunniffe NG, Prados F, Kanber B, Jones JL, Needham E, Georgieva Z, Rog D, Pearson OR, Overell J, MacManus D, Samson RS, Stutters J, Ffrench-Constant C, Gandini Wheeler-Kingshott CAM, Moran C, Flynn PD, Michell AW, Franklin RJM, Chandran S, Altmann DR, Chard DT, Connick P, Coles AJ. Brown JWL, et al. Among authors: jones jl. Lancet Neurol. 2021 Sep;20(9):709-720. doi: 10.1016/S1474-4422(21)00179-4. Lancet Neurol. 2021. PMID: 34418398 Clinical Trial.
New treatment strategies in multiple sclerosis.
Jones JL, Coles AJ. Jones JL, et al. Exp Neurol. 2010 Sep;225(1):34-9. doi: 10.1016/j.expneurol.2010.06.003. Epub 2010 Jun 12. Exp Neurol. 2010. PMID: 20547155 Review.
Remyelination varies between and within lesions in multiple sclerosis following bexarotene.
Brown JWL, Prados F, Altmann DR, Kanber B, Stutters J, Cunniffe NG, Jones JL, Georgieva ZG, Needham EJ, Daruwalla C, Wheeler-Kingshott CG, Connick P, Chandran S, Franklin R, MacManus D, Samson R, Coles A, Chard D. Brown JWL, et al. Among authors: jones jl. Ann Clin Transl Neurol. 2022 Oct;9(10):1626-1642. doi: 10.1002/acn3.51662. Epub 2022 Sep 17. Ann Clin Transl Neurol. 2022. PMID: 36116011 Free PMC article.
Spotlight on alemtuzumab.
Jones JL, Coles AJ. Jones JL, et al. Int MS J. 2009 Sep;16(3):77-81. Int MS J. 2009. PMID: 19878629 Review.
Campath-1H treatment of multiple sclerosis.
Jones JL, Coles AJ. Jones JL, et al. Neurodegener Dis. 2008;5(1):27-31. doi: 10.1159/000109935. Neurodegener Dis. 2008. PMID: 18075272 Review.
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.
Hill-Cawthorne GA, Button T, Tuohy O, Jones JL, May K, Somerfield J, Green A, Giovannoni G, Compston DA, Fahey MT, Coles AJ. Hill-Cawthorne GA, et al. Among authors: jones jl. J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):298-304. doi: 10.1136/jnnp-2011-300826. Epub 2011 Nov 5. J Neurol Neurosurg Psychiatry. 2012. PMID: 22056965
Immune competence after alemtuzumab treatment of multiple sclerosis.
McCarthy CL, Tuohy O, Compston DA, Kumararatne DS, Coles AJ, Jones JL. McCarthy CL, et al. Among authors: jones jl. Neurology. 2013 Sep 3;81(10):872-6. doi: 10.1212/WNL.0b013e3182a35215. Epub 2013 Aug 7. Neurology. 2013. PMID: 23925762 Free PMC article.
802 results